Form 4: iBio awards CEO 180,000 options; first vest 10/20/2026

Rhea-AI Filing Summary

iBio, Inc. (IBIO) reported an insider equity award. Martin Brenner was granted 180,000 stock options at an exercise price of $0.893 on 10/20/2025.

The options vest 25% on 10/20/2026, with the remainder vesting in equal quarterly installments over 36 months, and they expire on 10/19/2035. Following the grant, 180,000 derivative securities are beneficially owned directly. Brenner is the company’s Chief Executive Officer, Chief Scientific Officer, and a Director. The transaction was coded A (grant) on Form 4.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brenner Martin

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	180,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 180,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brenner Martin

(Last) (First) (Middle)

C/O IBIO, INC.

11750 SORRENTO VALLEY ROAD, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iBio, Inc. [ IBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)(1)	$0.893	10/20/2025		A		180,000		10/20/2026	10/19/2035	Common Stock	180,000	$0	180,000	D

Explanation of Responses:

1. These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, the remainder of the shares of common stock underlying the options granted will vest in equal quarterly installments over a 36-month period, provided that the reporting person remains employed by iBio, Inc.

Remarks:

Chief Executive Officer and Chief Scientific Officer

	/s/ Martin Brenner	10/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did iBio (IBIO) disclose in this Form 4?

A grant of 180,000 stock options to Martin Brenner at an exercise price of $0.893 on 10/20/2025.

What is the vesting schedule for the IBIO CEO’s options?

25% vests on 10/20/2026, and the remaining shares vest in equal quarterly installments over 36 months.

When do these iBio options expire?

The options expire on 10/19/2035.

How many derivative securities does the reporting person own after the grant?

Following the grant, 180,000 derivative securities are beneficially owned directly.

What was the Form 4 transaction code for the iBio option grant?

The transaction was coded A, indicating an award or grant.

What roles does the reporting person hold at iBio (IBIO)?

Martin Brenner serves as Chief Executive Officer, Chief Scientific Officer, and Director.